Esperion Therapeutics Inc (Esperion) is a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol-lowering therapies. The company develops oral therapies to treat patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate, Bempedoic acid is an ATP-citrate lyase inhibitor is in the clinical development phase that reduces elevated LDL-C levels in patients with hypercholesterolemia. The company also provides the development of bempedoic acid in a fixed-dose combination with ezetimibe, an LDL-C lowering therapy. Esperion is headquartered in Ann Arbor, Michigan, the US.
Headquarters
United States of America
Address
601 21st Street, Suite 300, Vero Beach, Florida, 32960
Website
www.esperion.com
Telephone
1 772 4532770
No of Employees
240
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ESPR (NASD)
Revenue (2022)
$116.3M
54.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
10.4%
(2022 vs 2021)
Market Cap*
$348.5M
Net Profit Margin (2022)
XYZ
41.9%
(2022 vs 2021)
* As of and is in US$
Esperion Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline: | NEXLIZET |
| Ezetimibe | NEXLETOL |
| Bempedoic Acid |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In March, the company secured approval from the United States Food and Drug Administration for broad new label expansions for NEXLETOL Tablets and NEXLIZET Tablets. |
| 2023 | Contracts/Agreements | In April, the company entered into an agreement with Currax Pharmaceuticals to co-promote NEXLETOL tablets and NEXLIZET tablets. |
| 2023 | Contracts/Agreements | In March, the company entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 33,170,747 shares of its common stock. |
Competitor Comparison
| Key Parameters | Esperion Therapeutics Inc | Cyclacel Pharmaceuticals Inc | BrainStorm Cell Therapeutics Inc | Lisata Therapeutics Inc | Stemline Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Vero Beach | Berkeley Heights | New York | Basking Ridge | New York |
| State/Province | Florida | New Jersey | New York | New Jersey | New York |
| No. of Employees | 240 | 12 | 29 | 25 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| J. Martin Carroll | Chairman | Executive Board | 2022 | 73 |
| Sheldon Koenig | Chief Executive Officer; President; Director | Executive Board | 2021 | 57 |
| Ben Halladay | Chief Financial Officer | Senior Management | 2022 | - |
| Betty Jean Swartz | Chief Strategy Officer | Senior Management | 2022 | - |
| JoAnne Micale Foody | Chief Medical Officer | Senior Management | 2021 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward